ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2025 · pp. 34–40
Kudriashov G.G., Krylova Yu.S., Zmitrichenko Yu.G., Tochilnikov G.V., Afafonov G.M., Vinogradova T.I., Yablonskii P.K.
Introduction. Up to 20% of tuberculosis patients suffer from malignant neoplasms. In this case, the combination of both diseases in the lung is a particular problem. More than 60% of patients cannot complete combination therapy due to drug-resistant MBT. The a…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2023 · pp. 51–57
Esmedlyaeva D.S., Alekseeva N.P., Dyakova M.E.
Introduction. The search for molecular markers of adverse treatment outcomes in individuals with pulmonary tuberculosis (PT) is relevant due to the worldwide increase in drug resistance of Mycobacterium tuberculosis (MBT) strains to anti-tuberculosis drugs (PT…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2023 · pp. 43–49
Kudriashov G.G., Nefedov A.O., Tochilnikov G.V., Zmitrichenko Yu.G., Krylova Yu.S., Dogonadze M.Z., Gavrilov P.V., Azarov A.A., Davydenkova E.A., Vinogradova T.I., Yablonskii P.K.
Introduction. One of the problems of modern medicine is the low efficiency of treatment of patients with a coexistence of lung cancer and active tuberculosis. Optimal treatment regimens for coexistence pathology have not been developed at present. In recent ye…